Publications by authors named "Nobuo Hatori"

Claim this Profile
E
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.

Diabetes Obes Metab· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease.
Shunichiro Tsukamoto, Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Tomohiko Kanaoka, Yutaka Hatori

Hypertens Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Yoshimi Muta, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daisuke Suzuki, Nobuo Hatori

Front Pharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Shunichiro Tsukamoto, Moritsugu Kimura, Yutaka Hatori

Cardiovasc Endocrinol Metab· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daiji Kawanami, Daisuke Suzuki, Nobuo Hatori

Diab Vasc Dis Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-sectional survey of hypertension management in clinical practice in Japan: the Kanagawa Hypertension Study 2021 conducted in collaboration with Japan Medical Association Database of Clinical Medicine.
Kazuo Kobayashi, Keiichi Chin, Nobuo Hatori, Takayuki Furuki, Hiroyuki Sakai

Hypertens Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome and risk factors associated with events in patients with atrial fibrillation treated with oral anticoagulants: The ASSAF-K registry.
Yutaka Hatori, Hiroyuki Sakai, Nobuo Hatori, Tomoyuki Kunishima, Atsuo Namiki

J Cardiol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of Japanese general practitioners' familiarity with nephrologists on the management of chronic kidney disease.
Tsuguru Hatta, Kazuo Kobayashi, Satoru Tatematsu, Yasunori Utsunomiya, Taisuke Isozaki, Nobuo Hatori

J Nephrol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Proportion of Long-term Response to Anti-N IgG Antibody after 12 Months for COVID-19 Subclinical Infections and a Longitudinal Survey for COVID-19 Subclinical Infections in 2021.
Ikuro Matsuba, Tetsuo Takuma, Nobuo Hatori, Masahiko Takai, Yoshiyuki Watanabe, Yutaka Hatori

Intern Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the first announced state of emergency owing to coronavirus disease 2019 on stress and blood pressure levels among patients with type 2 diabetes mellitus in Japan.
Shun Ito, Kazuo Kobayashi, Keiichi Chin, Shinichi Umezawa, Hareaki Yamamoto, Nobuo Hatori

J Diabetes Investig· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant treatment with insulin and sodium-glucose cotransporter 2 inhibitors was associated with the renal composite outcome in Japanese patients with type 2 diabetes and chronic kidney disease: A propensity score-matched analysis.
Masao Toyoda, Nobumichi Saito, Moritsugu Kimura, Nobuo Hatori, Kouichi Tamura

J Diabetes Investig· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Hiroyuki Sakai, Takayuki Furuki

Sci Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the 2013 and 2019 Nationwide Surveys on the Management of Chronic Kidney Disease by General Practitioners in Japan.
Satoru Tatematsu, Kazuo Kobayashi, Yasunori Utsunomiya, Tsuguru Hatta, Taisuke Isozaki, Nobuo Hatori

J Clin Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of stress induced by the first announced state of emergency due to coronavirus disease 2019 on outpatient blood pressure management in Japan.
Kazuo Kobayashi, Keiichi Chin, Shinichi Umezawa, Shun Ito, Hareaki Yamamoto, Nobuo Hatori

Hypertens Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polypharmacy influences the renal composite outcome in patients treated with sodium-glucose cotransporter 2 inhibitors.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Takayuki Furuki, Hiroyuki Sakai, Yutaka Hatori

Clin Transl Sci· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Kazuyoshi Sato, Masaaki Miyakawa

J Diabetes Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Hiroyuki Sakai, Takayuki Furuki

Diabetes Res Clin Pract· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections.
Ikuro Matsuba, Tetsuo Takuma, Nobuo Hatori, Masahiko Takai, Yoshiyuki Watanabe

Intern Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evaluation of noninferiority for renal composite outcomes between sodium-glucose cotransporter inhibitors in Japan.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Kazuyoshi Sato, Masaaki Miyakawa

Prim Care Diabetes· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nationwide questionnaire survey on the management of chronic kidney disease for general practitioners in Japan.
Satoru Tatematsu, Kazuo Kobayashi, Yasunori Utsunomiya, Taisuke Isozaki, Tsuguru Hatta, Nobuo Hatori

Clin Exp Nephrol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of questionnaire responses regarding awareness of Japanese Society of Hypertension guidelines for the management of hypertension between 2014 and 2019 in primary care.
Kazuo Kobayashi, Nobuo Hatori, Hiroyuki Sakai, Takayuki Furuki, Masaaki Miyakawa

Hypertens Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Takayuki Furuki, Hiroyuki Sakai

J Diabetes Investig· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Nobumichi Saito, Tomohiko Kanaoka, Yutaka Hatori

Diabetes Technol Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survey of the current status of subclinical coronavirus disease 2019 (COVID-19).
Ikuro Matsuba, Nobuo Hatori, Norihiko Koido, Yoshiyuki Watanabe, Futoshi Ebara

J Infect Chemother· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of long-term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney disease.
Takayuki Furuki, Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Hiroyuki Sakai

J Clin Hypertens (Greenwich)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis